Catheter Precision, Inc.(VTAK)Stock Analysis

VTAK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Catheter Precision, Inc. (VTAK), a Healthcare sector company. VTAK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $7.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Catheter Precision, Inc. reports quarterly revenue of $432.0K, net income of $-1.7M, free cash flow of $-2.8M. Top institutional holders of VTAK by reported 13-F value include GEODE CAPITAL MANAGEMENT,, MILLENNIUM MANAGEMENT, JANE STREET GROUP,, based on the most recent SEC filings. VTAK trades on the NYSE exchange and files with the SEC under CIK 1716621. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Catheter Precision, Inc. directly from SEC EDGAR.